The edinburgh addiction cohort: Recruitment and follow-up of a primary care based sample of injection drug users and non drug-injecting controls

BMC Public Health

Volumn 10, Issue , 2010, Pages

  MacLeod, John ^a   Copeland, Lorraine ^b   Hickman, Matthew ^a   McKenzie, James ^b   Kimber, Jo ^a,c   De Angelis, Daniela ^d   Robertson, James R ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b Muirhouse Medical Group   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADDICTION; ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CASE REPORT; CHILD; COMPARATIVE STUDY; FAMILY SIZE; FEMALE; FOLLOW UP; HUMAN; INTERVIEW; MALE; MIDDLE AGED; PATIENT SELECTION; PRIMARY HEALTH CARE; QUESTIONNAIRE; SUBSTANCE ABUSE; UNITED KINGDOM;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHILD; FAMILY CHARACTERISTICS; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; PATIENT SELECTION; PRIMARY HEALTH CARE; QUESTIONNAIRES; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS;

EID: 77949418256     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-10-101     Document Type: Article

References (50)

1. Global Perspectives on Drug Injecting. GV Stimson K Choopanya, Drug injecting and HIV infection: global dimensions and local responses London: University College London Press, Stimson GV, Des Jarlais DC, Ball A, 1998 1 21
2. Estimating long-term trends in the incidence and prevalence of opiate/injecting drug use and the number of ex-users: the use of back-calculation methods and opiate overdose deaths. D De Angelis M Hickman S Yang, American Journal of Epidemiology 2004 160 994 1004 10.1093/aje/kwh306 15522856
3. The medical complications of drug addiction and the medical assessment of the intravenous drug user. C Cherubin J Sapira, Annals of Internal Medicine 1993 119 10 1017 1028 8214979
4. Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. L Degenhardt W Hall M Warner-Smith, Sexually Transmitted Infections 2006 82 56 63 10.1136/sti.2005.019273 (Pubitemid 43901613)
5. The economic and social costs of Class A drug use in England and Wales, 2000. C Godfrey G Eaton, et al. Home Office Research Study 249 Home Office Research, Development and Statistics Directorate 2002
6. The role of sexual transmission of HIV infection among injection and non-injection drug users. S Strathdee S Sherman, Journal of Urban Health 2003 80 4 (Suppl 3) ii7 14 14713667
7. Drug use prevention among young people: a review of reviews. U Canning L Millward R Thara D Warm, London: Health Development Agency 2004
8. J Ward RP Mattick W Hall, Methadone Maintenance Treatment and Other Opioid Replacement Therapies Amsterdam: Harwood Academic Press 1997
9. Substitution treatment of injecting opioid users for prevention of HIV infection. L Gowing M Farrell R Bornemann R Ali, The Cochrane Library 2004 4 Oct 18
10. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence (Cochrane Review). RP Mattick C Breen J Kimber M Davoli R Breen, Cochrane Library 2002 2002 2
11. Methadone maintenance and addicts' risk of fatal heroin overdose. J Caplehorn MS Dalton F Haldar AM Petrenas JG Nisbet, Substance Use & Misuse 1996 31 2 177 196 10.3109/10826089609045806 8834006
12. Methadone treatment protects against HIV infections: two decades of experience in the Bronx, New York City. DM Hartel E Schoenbaum, Public Health Reports 1998 113 Suppl 1 107 115 9722816
13. Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in Baltimore, MD, 1988-2000. NG Shah N Galai DD Celentano D Vlahov SA Strathdee, Drug & Alcohol Dependence 2006 83 2 147 156 10.1016/j.drugalcdep.2005.11.007 (Pubitemid 44208952)
14. Mortality risk among new onset injection drug users. D Vlahov C Wang N Galai J Bareta S Mehta S Strathdee KE Nelson, Addiction 2004 99 946 954 10.1111/j.1360-0443.2004.00780.x 15265091
15. Heroin maintenance for chronic heroin dependents (Review). M Ferri M Davoli CA Perucci, Cochrane Collaboration, Cochrane Library 2005 2 1 19
16. Management of opioid withdrawal. L Gowing R Ali J White, Drug and Alcohol Review 2000 19 3 309 318 10.1080/713659366
17. Interventions for drug-using offenders in the courts, secure establishments and the community. A Perry S Coulton J Glanville C Godfrey J Lunn C McDougall Z Neale, Cochrane Database of Systematic Reviews 2006 3 D005193
18. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. MS Gordon T Kinlock R Schwartz K O'Grady, Addiction 2008 103 8 1333 1342 10.1111/j.1360-0443.2008.002238.x 18855822
19. P Hartsock S Genser (Eds), Longitudinal Studies of HIV Infection in Intravenous Drug Users: Methodological Issues in Natural History Research. Volume NIDA Research Monograph 109 Rockville, MA: National Institute on Drug Abuse 1991
20. Injecting drug use in Brighton, Liverpool, and London: best estimates of prevalence and coverage of public health indicators. M Hickman V Higgins V Hope M Bellis K Tilling A Walker J Henry, Journal of Epidemiology and Community Health 2004 58 766 771 10.1136/jech.2003.015164 15310803
21. National and regional estimates of the prevalence of opiate use and/or crack cocaine use 2005/06: a summary of key findings. G Hay M Gannon J MacDougall T Millar C Eastwood NP McKeganey, London: Home Office 2007
22. Estimating the prevalence of problematic drug use: A review of methods and their application. M Hickman C Taylor A Chatterjell L Degenhardt M Frischer G Hay K Tilling L Weissing P Griffiths R McKetin, Bulletin on Narcotics 2002 LIV 1/2 15 32
23. A national household survey of drug misuse in Britain: a decade of development. ME Ramsay E Percy, Addiction 2006 92 I 8 931 937
24. Overview of 5-year follow-up outcomes in the drug abuse treatment outcome studies (DATOS). RL Hubbard SG Craddock J Anderson, Journal of Substance Abuse Treatment 2003 25 3 125 134 10.1016/S0740-5472(03)00130-2 14670518
25. The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results. M Gossop J Marsden D Stewart T Kidd, Addiction 2003 98 3 291 303 10.1046/j.1360-0443.2003.00296.x 12603229
26. Abstinence and drug abuse treatment: results from the Drug Outcome Research in Scotland study. NP McKeganey M Bloor M Robertson J Neale J MacDougall, Drugs: Education Prevention and Policy 2006 13 6 537 550 10.1080/09687630600871987
27. A 33-year Follow-up of Narcotics Addicts. Y Hser V Hoffman C Grella D Anglin, Archives of General Psychiatry 2001 58 503 508 10.1001/archpsyc.58.5.503 11343531
28. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. D Vlahov JC Anthony A Munoz J Margolick KE Nelson DD Celentano L Solomon BF Polk, NIDA Research Monograph 109 1991 75 100
29. A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. EJ Van Ameijden JA Van den Hoek GH Mientjes RA Coutinho, Eur J Epidemiol 1993 9 3 255 262 10.1007/BF00146260 8405310
30. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. L Maher B Jalaludin KG Chant R Jayasuriya T Sladden JM Kaldor PL Sargent, Addiction 2006 101 10 1499 1508 10.1111/j.1360-0443.2006. 01543.x 16968352
31. Incidence of hepatitis C virus (HCV) among new injecting drug users in London. A Judd M Hickman S Jones T McDonald JV Parry GV Stimson, et al. British Medical Journal 2005 330 24 25 10.1136/bmj.38286.841227.7C 15533854
32. Epidemic of AIDS related virus (HTLV-III/LAV) infection among intravenous drug abusers. JR Robertson AB Bucknall PD Welsby JJ Roberts JM Inglis JF Peutherer RP Brettle, British Medical Journal (Clinical Research Ed) 1986 292 6519 527 529 10.1136/bmj.292.6519.527 3081158
33. Deaths, HIV infection, abstinence, and other outcomes in a cohort of injecting drug users followed up for 10 years. JR Robertson PJM Ronald G Raab AM Ross T Parpia, British Medical Journal 1994 309 369 372 8081134
34. Collecting retrospective data: accuracy of recall after 50 years judged against historical records. L Berney DB Blane, Social Science & Medicine 1997 45 519 525 10.1016/S0277-9536(97)00088-9 (Pubitemid 27455279)
35. D Collet, Modelling survival data in medical research London: Chapman & Hall 2 2003
36. D Hosmer S Lemeshow, Applied Survival Analysis: Regression Modeling of Time to Event Data New York: John Wiley & Sons 1999
37. Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. N Craine M Hickman JV Parry J Smith A Walker B Nix M May T MacDonald M Lyons, Epidemiology and Infection 2009 137 9 1255 1265 10.1017/S095026880900212X 19224654
38. K Rothman S Greenland, Modern Epidemiology Philladelphia: Lippincott-Raven 1998
39. Psychiatric Morbidity among Adults living in Private Households, 2000. N Singleton R Bumpstead M O'Brien A Lee H Meltzer, London: Office of National Statistics 2001
40. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants: Basic findings from the National Comorbidity Survey. JC Anthony LA Warner RC Kessler, Experimental and Clinical Psychopharmacology 1994 2 244 268 10.1037/1064-1297.2.3.244
41. Estimating Hepatitis C Prevalence in England and Wales by synthesising evidence from multiple data sources. Assessing data conflict and model fit. MJ Sweeting D De Angelis M Hickman AE Ades, Biostatistics 2008 9 4 715 34 10.1093/biostatistics/kxn004 18349037
42. Estimating the prevalence of ex-injecting drug use in the population. MJ Sweeting D De Angelis AE Ades M Hickman, Statistical Methods in Medical Research 2009 18 4 381 95 10.1177/0962280208094704 19036912
43. Incidence of heroin use has declined dramatically in Zurich, Switzerland. C Nordst R Stohler, Lancet 2006 367 9525 1830 1834 10.1016/S0140-6736(06)68804- 1 16753485
44. Trajectories of heroin addiction: growth mixture modeling results based on a 33-year follow-up study. Y Hser D Huang C CP D Anglin, Evaluation Review 2007 31 6 548 563 10.1177/0193841X07307315 17986707
45. Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. F Termorshuizen A Krol M Prins R Geskus W van den Brink EJ Van Ameijden, Drug & Alcohol Dependence 2005 79 2 231 240 10.1016/j.drugalcdep.2005.01.013 (Pubitemid 40942113)
46. Longitudinal patterns of drug injection behaviour in the ALIVE study cohort, 1988-2000: description and determinants. N Galai M Safaeien D Vlahov A Bolotin DD Celentano, American Journal of Epidemiology 2003 158 7 695 704 10.1093/aje/kwg209 14507606
47. Economic analysis of costs and consequences of the treatment of drug misuse: two year outcome data from the National Treatment Outcome Research Study (NTORS). C Godfrey D Stewart M Gossop, Addiction 2004 99 6 697 707 10.1111/j.1360-0443.2004.00752.x 15139868
48. T Babor JC Higgins-Biddle JS Saunders M Monteiro, The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Care Geneva: WHO 2 2001
49. The Hospital Anxiety And Depression Scale. AS Zigmond RP Snaith, Acta Psychiatr Scand 1983 67 361 370 10.1111/j.1600-0447.1983.tb09716.x 6880820
50. EQ-5D : a measure of health status from the EuroQol Group. R Rabin F de Charro, Annals of Medicine 2001 33 5 337 343 10.3109/07853890109002087 11491192